Aquestive Therapeutics, Inc. (AQST)
Automate Your Wheel Strategy on AQST
With Tiblio's Option Bot, you can configure your own wheel strategy including AQST - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AQST
- Rev/Share 0.5678
- Book/Share -0.638
- PB -5.5483
- Debt/Equity -0.6423
- CurrentRatio 4.8732
- ROIC -0.4872
- MktCap 351620766.0
- FreeCF/Share -0.5135
- PFCF -7.1701
- PE -6.2328
- Debt/Assets 0.3828
- DivYield 0
- ROE 1.0741
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AQST | Oppenheimer | -- | Outperform | -- | $7 | June 2, 2025 |
| Initiation | AQST | Cantor Fitzgerald | -- | Overweight | -- | $17 | Dec. 17, 2024 |
News
Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Stanley Kristen Kluska - Cantor Fitzgerald Jason Butler - Citizens JMP Raghuram Selvaraju - HC Wainwright Dennis Resnick - Raymond James Nelson Cox - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the Aquestive Therapeutics First Quarter 2025 Earnings …
Read More
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Positive
Aquestive currently plays small ball with a handful of approved products that offer no adequate financial potential. Its recently approved Libervant, which offered greater revenue opportunity, is mired in litigation. Aquestive's Anaphylm, which is set for an imminent FDA filing, has blockbuster potential.
Read More
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that multiple presentations highlighting results from the investigational use of Anaphylm epinephrine sublingual film in the treatment of severe allergic reactions, including anaphylaxis, will be featured at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting. The meeting will take place February 28 - March 3, 2025, in San Diego, CA.
Read More
About Aquestive Therapeutics, Inc. (AQST)
- IPO Date 2018-07-25
- Website https://www.aquestive.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Daniel Barber
- Employees 142